Login / Signup

Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S.

Jerald SadoffGlenda E GrayAn VandeboschVicky CárdenasGeorgi ShukarevBeatriz GrinsztejnPaul A GoepfertCarla TruyersIlse Van DrommeBart SpiessensJohan VingerhoetsJerome CustersGert ScheperMerlin L RobbJohn TreanorMartin F RyserDan H BarouchEdith SwannMary A MarovichKathleen M NeuzilLawrence CoreyJeffrey StoddardKarin HardtJavier Ruiz-GuiñazúMathieu Le GarsHanneke SchuitemakerJohan Van HoofFrank StruyfMacaya Douoguihnull null
Published in: The New England journal of medicine (2022)
A single dose of Ad26.COV2.S provided 52.9% protection against moderate to severe-critical Covid-19. Protection varied according to variant; higher protection was observed against severe Covid-19, medical intervention, and death than against other end points and lasted for 6 months or longer. (Funded by Janssen Research and Development and others; ENSEMBLE ClinicalTrials.gov number, NCT04505722.).
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • early onset
  • randomized controlled trial
  • healthcare
  • high intensity
  • drug induced
  • machine learning
  • deep learning
  • neural network